# Debate prop_0635__grok-4.6-high__kimi-k3__s0__tpl_placement_active_20260813a

- topic_id: prop_0635
- proposition: AI model providers should face product-liability-style responsibility for foreseeable harms caused by deployed model behavior when reasonable safeguards were not implemented.
- model_pro: grok-4.6-high
- model_con: kimi-k3
- side_swap: False

## Turn 1: PRO Opening

- model: grok-4.6-high
- raw_words: 319
- clipped_words: 319
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6], [P1.7], [P1.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] When a company designs a product, chooses which safety features to include, and releases it into ordinary use, it already lives under a familiar rule: if foreseeable harm follows from a missing reasonable safeguard, the manufacturer answers for it. That is product liability. Deployed AI models belong under the same rule.
[P1.2] The proposition is not that labs must prevent every crime, every hallucination, or every clever jailbreak. It is narrower and more ordinary. Responsibility attaches when three things line up: the harm was foreseeable, it came from the model's deployed behavior, and reasonable safeguards were not implemented. That is design-defect logic, not omniscience.
[P1.3] Providers control the only levers that matter at scale. They set the training objective, the refusal surface, the default deployment stack, the monitoring, and the patch cycle. Users cannot audit weights. Most integrators cannot rebuild alignment.
[P1.4] If a model will, in ordinary use, invent medical dosages, walk through obvious fraud, or fail basic child-safety filters, the people who shipped that behavior knew enough to add guards. They are the least-cost avoiders.
[P1.5] Leave the rule off the table and the incentive is perverse. Capability ships first. Safety becomes a press release. The upside stays private; the injuries land on people who never chose the architecture.
[P1.6] We do not accept that bargain for cars that skip brakes or drugs that skip warnings. A model that generates instructions is not a passive hammer. It is a product whose behavior was designed, tested, and released.
[P1.7] Reasonable is not a mystery. It is what a prudent provider, with the information available at deployment, would have implemented: refusals for obvious criminal planning, filters for high-stakes false medical advice, monitoring for known abuse patterns. Foreseeability already excludes freak edge cases. The duty is not a riskless mind.
[P1.8] It is an end to treating cheap, known failure modes as someone else's problem. That is the path: make the designer internalize foreseeable, preventable product behavior.

## Turn 2: CON Opening

- model: kimi-k3
- raw_words: 326
- clipped_words: 326
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7], [C1.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C1.1] The car-without-brakes analogy sounds decisive until you ask the obvious question: what is the brake? A brake has a specification — it stops the car or it doesn't. A general-purpose model has no specification for "correct behavior" across the open-ended infinity of things users ask it. Product liability presupposes a defect, and a defect presupposes a design the product failed to match.
[C1.2] There is no such design for emergent model behavior; there never could be. The entire doctrine depends on a thing this technology does not have.
[C1.3] That gap poisons every prong of the motion. "Foreseeable" becomes everything: a general-purpose model can be asked anything, so any harm is imaginable in advance. "Reasonable safeguards" becomes whatever a jury, after the injury, wishes had existed — because AI safety has no settled standard of care, and the state of the art moves quarterly. This is not negligence.
[C1.4] It is strict liability in negligence's clothing, with the standard written retroactively, in hindsight, by litigation.
[C1.5] PRO calls providers the least-cost avoiders. They are not. The deployer who hands a model to patients, students, or customers knows the stakes and controls the context; the cheap, decisive safeguards — domain filters, human review, or simply not using a chatbot for dosing decisions — live there. Forcing universal refusals upstream taxes every lawful user to guard against someone else's misuse.
[C1.6] And the costs concentrate: incumbents absorb open-ended liability as a licensing fee, while startups, open-source projects, and university labs cannot. This motion builds a moat, not a safeguard.
[C1.7] The gap PRO worries about is already covered: negligence, consumer protection, fraud law, and sector regulators like the FDA police the contexts where harm actually lands. What this motion adds is not protection but uncertainty — and uncertainty does not make models safer. It makes them scarcer, more closed, more expensive, and built only by firms rich enough to be sued.
[C1.8] Hold deployers to their contexts. Let standards mature before courts invent them retroactively.

## Turn 3: PRO Rebuttal 1

- model: grok-4.6-high
- raw_words: 289
- clipped_words: 289
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7], [P2.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P2.1] "The brake" is a red herring. Product liability never needed a single specification of correct behavior for every use. Cars have no spec for every crash; drugs have no spec for every reaction. Design-defect doctrine asks whether the product, as released, posed a foreseeable, unreasonable risk a prudent manufacturer would have guarded against.
[P2.2] Models have designed behavior: training objectives, refusal surfaces, defaults. When that design produces known failure modes in ordinary use, the missing safeguard is the defect. There is a design. It is the one they shipped.
[P2.3] CON says "foreseeable" becomes everything. Only if you erase the rest of the test. The motion requires three conditions at once: foreseeable harm, from deployed model behavior, after reasonable safeguards were omitted. A prudent provider at deployment need not imagine infinity.
[P2.4] It must address failure modes already visible in ordinary use. That is not retroactive strict liability. It is the foresight duty every manufacturer already faces.
[P2.5] Deployers matter, but they do not control the levers CON claims. A clinic can add review; it cannot rewrite a model's tendency to invent dosages. Source safeguards stop the same defect from being copied into every context. Reasonable does not mean taxing every lawful user with blanket refusals; it means guards a prudent provider would add for known, high-stakes failures.
[P2.6] Making only downstream actors compensate for upstream design is how preventable harm scales.
[P2.7] The moat argument cuts the wrong way. Startups already sell physical products under this rule. CON's uncertainty is the ordinary cost of shipping designed behavior into the world. Negligence and sector rules police some uses; they do not make the designer internalize missing, known guards at the only layer that reaches every user.
[P2.8] That is the gap. Close it at the source.

## Turn 4: CON Rebuttal 1

- model: kimi-k3
- raw_words: 344
- clipped_words: 340
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7]
- cited_claim_ids: [P2.2]
- missing_claim_id_refs: (none)

[C2.1] "The clinic cannot rewrite the weights." True — and irrelevant. The clinic does not need the weights. It needs retrieval against a formulary, dose verification, a pharmacist's sign-off, or simply the decision not to let a raw chatbot prescribe.
[C2.2] Those guards are cheap, decisive, and only the deployer can calibrate them, because only the deployer knows the stakes. The "copied into every context" logic cuts against PRO: precisely because the model is general-purpose, an upstream refusal tuned for fraud degrades lawful security research; a dosing filter degrades pharmacology education. Source-level guards are blind to context, so they are always overbroad or underbroad.
[C2.3] Now the circularity. "There is a design. It is the one they shipped" [P2.2] proves too much: it makes every output designed, so every bad output becomes a defect by definition. That is strict liability in negligence's clothing, and PRO's limiter — failure modes "already visible in ordinary use" — does not narrow it, because a general-purpose model has no bounded ordinary use.
[C2.4] A car is judged against the crash it was in: a bounded event, one ordinary use called driving. This product's ordinary use is everything users type into it, across medicine, crime, and children simultaneously. After any injury, some guard will always look addable in hindsight; with no settled standard of care in a field whose state of the art moves quarterly, the jury writes the spec retroactively. That is the defect.
[C2.5] The startup comparison fails the same way. A toaster startup faces a bounded duty in one context. A lab shipping a general model faces unbounded duty in every domain at once — and for open-source releases, the motion makes publication itself the liability event. Nor is this uncertainty "the ordinary cost of shipping designed behavior": ordinary product liability rests on mature standards of care.
[C2.6] None exist here.
[C2.7] Strip the analogy away and the motion adds exactly one thing to negligence, fraud, and sector law: a retroactive standard imposed at the layer least able to know the context. That prices out everyone but firms rich [clipped]

## Turn 5: PRO Pressure Questions

- model: grok-4.6-high
- raw_words: 70
- clipped_words: 70
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C1.1], [C2.2]
- missing_claim_id_refs: (none)

[P3.1] Q1: You say a model has “no specification” [C1.1]. If a consumer chatbot invents lethal dosages in ordinary medical queries and no available refusal or warning was shipped, do you still deny a defect?
[P3.2] Q2: You claim only the deployer can add cheap, decisive guards [C2.2]. When the user is the deployer, and only the provider can stop a known failure in the model itself, does the designer owe nothing?

## Turn 6: CON Pressure Questions

- model: kimi-k3
- raw_words: 99
- clipped_words: 99
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: [P2.4], [P1.7]
- missing_claim_id_refs: (none)

[C3.1] Q1: You limit the duty to failure modes "already visible in ordinary use" [P2.4]. But a general-purpose model's ordinary use is everything users type into it. Before an injury occurs, what principled test separates a foreseeable failure mode from a merely imaginable one — or does "visible" only become visible in hindsight?
[C3.2] Q2: You define "reasonable" as what a prudent provider would implement [P1.7]. In a field with no settled standard of care, where the state of the art moves quarterly, name the benchmark a provider can consult at deployment — or concede the jury writes the spec afterward.

## Turn 7: PRO Rebuttal 2

- model: grok-4.6-high
- raw_words: 294
- clipped_words: 294
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5], [P4.6], [P4.7], [P4.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P4.1] A1: Visibility is judged from information available at deployment, not after the injury. The test is whether the provider's own evals, red-team results, incident reports, and already-known failure classes already showed that harm in uses the product is offered for. Inventing lethal dosages on routine medical questions is in that class now. A novel, unreported attack path is not.
[P4.2] Ordinary use is not every string a user might type; it is the marketed, observed uses a prudent shipper already sees. That is foresight. It does not become visible only in the lawsuit.
[P4.3] A2: The benchmark is contemporaneous practice: safeguards already available and used by prudent providers at the moment of release. A field that moves quarterly still has a snapshot. Early cars and drugs were judged against what makers then knew and could implement, not against a future code. The jury asks whether those then-available guards were omitted.
[P4.4] It does not write next quarter's spec.
[P4.5] Those answers collapse the hindsight story. Foreseeability is a documented class, not infinity. Reasonableness is frozen at shipment, not invented afterward. Calling every output a defect is the misread: the defect is the omitted guard, not the bad answer alone.
[P4.6] What remains is a plea that "no settled standard" means no source duty at all. That is how known failures stay cheap.
[P4.7] The remaining clash is simple. Only-deployer guards fail when the user is the deployer and cannot rewrite a model that invents dosages or walks through obvious fraud. Context filters cannot fix the product. Source duty is not a blanket tax on lawful research; it is the missing refusal, warning, or monitor a prudent provider would already have added.
[P4.8] Wait for mature codes and the injuries stay externalized. Internalize them at the only layer that reaches every user.

## Turn 8: CON Rebuttal 2

- model: kimi-k3
- raw_words: 326
- clipped_words: 326
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5], [C4.6], [C4.7]
- cited_claim_ids: [P4.1], [P4.3]
- missing_claim_id_refs: (none)

[C4.1] A1: I deny the mechanism, not the responsibility. A chatbot inventing lethal dosages in queries it is marketed to answer is already reachable: negligent failure to warn, consumer-protection law, FDA oversight once offered for clinical use. Notice what the question requires: a failure already known, cheap to block, ignored anyway — ordinary negligence with an actual benchmark. The motion's distinctive work lies beyond that easy case, in the unbounded space where no safeguard spec exists and the jury writes one.
[C4.2] PRO's best example is exactly where the motion adds nothing.
[C4.3] A2: When the user is the deployer, the designer owes honesty: accurate claims, disclosure of known limits, no false safety marketing. "Only the provider can stop it" quietly assumes the failure is already known — a user asking a chatbot for dosing can verify, and known failure modes can be disclosed.
[C4.4] But grant the hard case: a known, cheap-to-block failure ignored. Negligence covers that today. What the motion adds is liability for the not-yet-known — and [P4.1] defines foreseeability through the provider's own evals and incident reports. That immunizes whoever does not look.
[C4.5] Diligent red-teaming documents more "visible" failures and buys more liability; skipped testing stays clean. A tax on transparency is not a safety rule.
[C4.6] Those two answers converge, and the convergence concedes the debate. If reasonableness is "safeguards already available and used by prudent providers" [P4.3], the rule only ever punishes laggards — the first injury of every new failure class is free, because nothing is "visible" until it happens. And the quarterly "snapshot" has no codified content: a jury still reconstructs what was "available and used" from dueling experts, hindsight entering through the evidentiary door.
[C4.7] Meanwhile my costs stand unrebutted: open-source publication as the liability event, the incumbent moat, context-blind upstream filters. A rule that punishes the diligent, exempts the first victim, and duplicates negligence exactly where cases are easy is not a safety regime. It is litigation in search of a standard.

## Turn 9: PRO Closing

- model: grok-4.6-high
- raw_words: 184
- clipped_words: 184
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4], [P5.5]
- cited_claim_ids: [C4.1]
- missing_claim_id_refs: (none)

[P5.1] CON now admits the decisive case. A model that invents lethal dosages in queries it is marketed to answer is already wrongful. They only deny the mechanism [C4.1]. That is enough.
[P5.2] Once foreseeable harm comes from shipped model behavior after a cheap known guard was omitted, the remaining question is who answers. CON offers warnings, clinic filters, and existing negligence. Those fail when the user is the deployer. A disclosure does not rewrite the product.
[P5.3] A parent or student who simply opened the chatbot cannot add the missing review. The designer still controls the only lever that reaches every user.
[P5.4] Renaming the duty "negligence" does not close that gap. It leaves the party that chose the refusals, the defaults, and the release able to externalize known failures until someone else happens to catch them. Product-liability-style responsibility exists for exactly that bargain: if you design the behavior and skip a reasonable safeguard, the injury is yours.
[P5.5] The hindsight story is already answered. Visibility is contemporaneous, not invented after the fact. The cheap, documented failure still needs an owner. Without this rule, it never gets one.

## Turn 10: CON Closing

- model: kimi-k3
- raw_words: 192
- clipped_words: 192
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4]
- cited_claim_ids: [P5.1], [P5.5], [P4.3], [P4.1]
- missing_claim_id_refs: (none)

[C5.1] PRO's closing concedes the debate's structure. "CON admits the decisive case" [P5.1] — yes, and that admission is the argument. A chatbot marketed for medical queries that invents lethal doses, the guard known and ignored, is wrongful under negligence, consumer-protection, and sector law today. "The cheap, documented failure still needs an owner" [P5.5] — it has three.
[C5.2] A motion whose parade case is already owned has no work to do.
[C5.3] So its distinctive work must lie beyond the documented failure — and there it collapses. Reasonableness frozen at "safeguards already available and used by prudent providers" [P4.3] only ever punishes laggards: the first victim of every new failure class goes uncompensated, because nothing is "used" until someone bleeds. And foreseeability defined by the provider's own evals [P4.1] taxes diligence: red-team thoroughly and you author your own liability; skip testing and stay clean. That point stood unanswered in PRO's final speech.
[C5.4] The choice was never duty versus no duty. It is contextual law that already works versus a retroactive standard that duplicates negligence where cases are easy, exempts the first injury, and fines the honest. That is not a safety regime. Vote CON.
